- Report
- August 2026
- 196 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- January 2026
- 280 Pages
Global
From €2695EUR$3,000USD£2,302GBP
- Report
- May 2026
- 150 Pages
Global
From €2505EUR$2,789USD£2,140GBP
- Report
- May 2026
- 100 Pages
Global
From €2424EUR$2,699USD£2,071GBP
- Report
- August 2025
- 194 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- May 2024
- 132 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- May 2024
- 131 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- October 2023
- 145 Pages
Global
From €2829EUR$3,150USD£2,417GBP
- Report
- August 2024
- 80 Pages
Japan
From €3144EUR$3,500USD£2,685GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2695EUR$3,000USD£2,302GBP
- Report
- February 2024
- 360 Pages
Global
From €7140EUR$7,950USD£6,099GBP
- Report
- May 2024
- 132 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- December 2023
- 140 Pages
Global
From €3997EUR$4,450USD£3,414GBP
- Report
- April 2025
- 137 Pages
Asia Pacific
From €3099EUR$3,450USD£2,647GBP
- Report
- April 2025
- 136 Pages
Middle East, Africa
From €3099EUR$3,450USD£2,647GBP
- Report
- July 2024
- 150 Pages
Global
From €3997EUR$4,450USD£3,414GBP
- Report
- November 2020
- 199 Pages
Global
€4042EUR$4,500USD£3,453GBP
- Report
- August 2026
- 50 Pages
Global
From €2380EUR$2,650USD£2,033GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more